Trials / Completed
CompletedNCT05345561
Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
A Prospective, Natural History Study to Assess the Occurrence of HPA-1a Alloimmunization in Women Identified at Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 14,390 (actual)
- Sponsor
- Rallybio · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A prospective, non-interventional, natural history study to assess the occurrence of higher FNAIT risk across a broad population of different racial and ethnic characteristics and the occurrence of HPA-1a alloimmunization in these women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Clinical data collection | Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed. |
Timeline
- Start date
- 2022-03-14
- Primary completion
- 2025-01-31
- Completion
- 2025-10-10
- First posted
- 2022-04-26
- Last updated
- 2026-03-06
Locations
28 sites across 7 countries: United States, Canada, Germany, Netherlands, Norway, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT05345561. Inclusion in this directory is not an endorsement.